Bavarian Nordic AS (BVNKF) reports a robust 62% revenue increase, driven by vaccine success and strategic government ...

Both the FDA and EMA have suspended Ixchiq’s use in older adults after post-marketing serious adverse events that include two ...

European stock markets saw gains. Germany's DAX reached a record high. Investors felt relieved by signs of a possible ease in ...

Bavarian Nordic A/S ( ($BVNRY) ) has released its Q1 earnings. Here is a breakdown of the information Bavarian Nordic A/S presented to its ...

Bavarian Nordic A/S (($BVNRY)) has held its Q1 earnings call. Read on for the main highlights of the call. Bavarian Nordic’s recent earnings call ...

European shares extended gains on Friday, with Germany's DAX index closing at an all-time high, as signs of easing global ...

Bavarian Nordic faced a challenging close to 2024, with Q3 revenue falling 26% compared to the same interval in 2023.

The earnings before interest, tax, depreciation and amortization margin rose to 31% from 3%, and Bavarian Nordic maintained guidance for a full-year EBITDA margin of 26%-30% with revenue still seen at ...

In Europe, the Stoxx Europe 600 climbed 0.4% in morning trading. Bavarian Nordic rose 14.1% and Sonova Holding added 6.5%. On the other hand, Orkla lost 5.2%, and Kongsberg Gruppen slipped 4.4%. The ...

Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results and business progress for the first three months of 2025. Revenue for the first three ...

Discover Emergent BioSolutions' Q1 2025 progress: revenue growth, improved liquidity, NARCAN updates, and strategic outlook.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Bavarian Nordic’s Vimkunya (recombinant, adsorbed ...